iSonea picks manufacturing partner for AirSonea
iSonea (ASX:ISN) has selected Hong Kong-based Refined Manufacturing to produce its AirSonea mobile wheeze monitoring device.
iSonea, which plans to launch the product in the Australian market in September, had already engaged Refined to produce several prototype AirSonea units. Refined will now scale up to prepare for commercial manufacturing.
“Finding a source with extensive experience and scalability to manufacture products that are smart-phone compatible was a crucial step in our transition to commercial production,” iSonea CEO Michael Thomas said.
AirSonea will allow patients to track and share acoustic respiratory monitoring data via smart phones.
Last week, iSonea released the results of a survey suggesting that 80% of Australian GPs surveyed would recommend AirSonea to their patients.
The company also recently unveiled AsthmaSense cloud, a cloud-based asthma monitoring tool.
iSonea shares were trading 8.11% higher at $0.40 as of around 1.30 pm on Wednesday.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
